Jefferies Reiterates Buy Rating, $36 PT on Incyte Corporation Despite PML Case
In a report published Monday, Jefferies analyst Thomas Wei reiterated a Buy rating and $36.00 price target on Incyte Corporation (NASDAQ: INCY).
In the report, Wei noted, “INCY today disclosed a 75-year old male patient developed PML, a rare brain infection, while taking Jakafi. We still believe that the overall risk-benefit profile of Jakafi is favorable and note that the causal relationship between Jakafi and the PML case is unclear with spontaneous reports of PML in the myelofibrosis literature, and there has been a favorable trend on overall survival seen in the Phase 3 trials.”
Incyte Corporation closed on Friday at $24.84.
Latest Ratings for INCY
|Apr 2016||BMO Capital||Initiates Coverage on||Outperform|
|Mar 2016||Morgan Stanley||Initiates Coverage on||Overweight|
|Feb 2016||Leerink Swann||Maintains||Outperform|
© 2016 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.